- Email: [email protected]
4847251 Pyridazinone derivatives, and pharmaceutical compositions containing them
vi
New Patents
4845118 SUBSTITUTED THIENOIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS INHIBITORS OF GASTRIC ACID SECRETION Hans-Jochen Lang, Robert Rippel, Andreas W Herling, Klau Weidmann, Hofheim am Taunus, Federal Republic Of Germany assigned to Hoechst Aktiengesellschaft The invention relates to compounds of the formula See Patent for Chemical Structure in which A represents See Patent for Chemical Structure (a) SR1 orR2 (b) R2SR1 (c) T denotes -S-, -SOor -SO2-, and R1 to R9 have the meanings given in the description, to a process for their preparation, to pharmaceutical compositions containing them, and to their use as inhibitors of gastric acid secretion.
4847077 CONTROLLED RELEASE PHARMACEUTICAL PREPARATIONS Yegnaswam Raghunathan assigned to Pennwalt Corporation Controlled release pharmaceutical preparations containing coated sulfonic acid cationic exchange resin drug complex particles, the resin particles having been treated, prior to coating, with about 15 to 25% by weight of glycerin, based on the combined weight of the glycerin and the drug resin complex particles.
4847091 PHARMACEUTICAL COMPOSITION INCLUDING SODIUM CROMOGLYCATE Lisbeth Ilium, Nottingham, United Kingdom assigned to Fisons plc Pharmaceutical compositions comprising microspheres incorporating sodium cromogly-
cate, wherein the microspheres comprise material having ion-exchange properties.
4847092 ORALLY ADMINISTERABLE SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS Arvind Thakkar, Lowell Gibson assigned to Eli Lilly and Company This invention provides orally administerable pharmaceutical formulations having a semisolid matrix containing a hydrophilic substance capable of creating channels in a hydrophobic carrier matrix thereby providing a sustained rate of release of an active agent from the formulation.
4847251 PYRIDAZINONE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Alfred Mertens, Saal Wolfgang Von Der, Bern Muller-Beckmann, Gisbert Sponer, Schriesheim, Federal Republic Of Germany assigned to Boehringer Mannheim GmbH The present invention provides pyridazinone derivatives of the general formula: See Patent for Chemical Structure (I) wherein Het is a mono- or bicyclic heterocycle with one or two nitrogen atoms, B-C is a -CHR1-CH2-, -CR1 double bondCH-, -CH R 1-O-, -O-CHR 1-, -CHR I-NHor -NH-CHR1- group, R1 being a hydrogen atom or an alkyl radical, and A is an amiono, alkylcarbonylamino, aminocarbonylamino, aminothiocarbonylamino, alkylaminothiocarbonylamino, alkylamionocarbonylamino, N'cyanoguanidino or N'-cyano-N"alkylguanidino group, a substituted phenyl ring or heterocycle attached via a nitrogen or sulphur atom, or a mono- or bicyclic substituted heterocycle with 1 to 3 nitrogen atoms, one ring nitrogen atom being directly attached to Het; as well as the physiologically acceptable salts thereof. The present invention also provides processes for the preparation of these pyridazinone drivatives and pharmaceutical compositions containing them for the treatment of heart and circulatory diseases.
New Patents
4845118 SUBSTITUTED THIENOIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS INHIBITORS OF GASTRIC ACID SECRETION Hans-Jochen Lang, Robert Rippel, Andreas W Herling, Klau Weidmann, Hofheim am Taunus, Federal Republic Of Germany assigned to Hoechst Aktiengesellschaft The invention relates to compounds of the formula See Patent for Chemical Structure in which A represents See Patent for Chemical Structure (a) SR1 orR2 (b) R2SR1 (c) T denotes -S-, -SOor -SO2-, and R1 to R9 have the meanings given in the description, to a process for their preparation, to pharmaceutical compositions containing them, and to their use as inhibitors of gastric acid secretion.
4847077 CONTROLLED RELEASE PHARMACEUTICAL PREPARATIONS Yegnaswam Raghunathan assigned to Pennwalt Corporation Controlled release pharmaceutical preparations containing coated sulfonic acid cationic exchange resin drug complex particles, the resin particles having been treated, prior to coating, with about 15 to 25% by weight of glycerin, based on the combined weight of the glycerin and the drug resin complex particles.
4847091 PHARMACEUTICAL COMPOSITION INCLUDING SODIUM CROMOGLYCATE Lisbeth Ilium, Nottingham, United Kingdom assigned to Fisons plc Pharmaceutical compositions comprising microspheres incorporating sodium cromogly-
cate, wherein the microspheres comprise material having ion-exchange properties.
4847092 ORALLY ADMINISTERABLE SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS Arvind Thakkar, Lowell Gibson assigned to Eli Lilly and Company This invention provides orally administerable pharmaceutical formulations having a semisolid matrix containing a hydrophilic substance capable of creating channels in a hydrophobic carrier matrix thereby providing a sustained rate of release of an active agent from the formulation.
4847251 PYRIDAZINONE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Alfred Mertens, Saal Wolfgang Von Der, Bern Muller-Beckmann, Gisbert Sponer, Schriesheim, Federal Republic Of Germany assigned to Boehringer Mannheim GmbH The present invention provides pyridazinone derivatives of the general formula: See Patent for Chemical Structure (I) wherein Het is a mono- or bicyclic heterocycle with one or two nitrogen atoms, B-C is a -CHR1-CH2-, -CR1 double bondCH-, -CH R 1-O-, -O-CHR 1-, -CHR I-NHor -NH-CHR1- group, R1 being a hydrogen atom or an alkyl radical, and A is an amiono, alkylcarbonylamino, aminocarbonylamino, aminothiocarbonylamino, alkylaminothiocarbonylamino, alkylamionocarbonylamino, N'cyanoguanidino or N'-cyano-N"alkylguanidino group, a substituted phenyl ring or heterocycle attached via a nitrogen or sulphur atom, or a mono- or bicyclic substituted heterocycle with 1 to 3 nitrogen atoms, one ring nitrogen atom being directly attached to Het; as well as the physiologically acceptable salts thereof. The present invention also provides processes for the preparation of these pyridazinone drivatives and pharmaceutical compositions containing them for the treatment of heart and circulatory diseases.